stafford semaglutide & tirzepatide ESC 2025: study supports use of semaglutide, tirzepatide in cardiometabolic HFpEF patients Semaglutide vs Tirzepatide, which is

Similar to the findings in non-transplant settings, PTDM has been shown to be associated with an increased risk of cardiovascular disease and infectious complications [1]

Tirzepatide and other GLP-1 RA drugs may cause severe and deadly side effects, including serious gastrointestinal problems, kidney failure, gallbladder problems and thyroid cancer

Unfortunately, screening rates remain low, with less than 50% of patients with diabetes mellitus receiving appropriate ophthalmic care through referrals from primary care physicians

Orlistat works by blocking the absorption of fat

Were not necessarily seeing an increase in fillers for weight loss